title: In-vitro activity of solithromycin against anaerobic bacteria from the normal intestinal microbiota.
abstract: Solithromycin is a novel fluoroketolide with high activity against bacteria associated with community-acquired respiratory tract infections as well as gonorrhea. However, data on the activity of solithromycin against anaerobic bacteria from the normal intestinal microbiota are scarce. In this study, 1024 Gram-positive and Gram-negative anaerobic isolates from the normal intestinal microbiota were analyzed for in-vitro susceptibility against solithromycin and compared to azithromycin, amoxicillin/clavulanic acid, ceftriaxone, metronidazole and levofloxacin by determining the minimum inhibitory concentration (MIC). Solithromycin was active against Bifidobacteria (MIC50, 0.008 mg/L) and Lactobacilli (MIC50, 0.008 mg/L). The MIC50for Clostridia, Bacteroides, Prevotella and Veillonella were 0.5, 0.5, 0.125 and 0.016 mg/L, respectively. Gram-positive anaerobes were more susceptible to solithromycin as compared to the other antimicrobials tested. The activity of solithromycin against Gram-negative anaerobes was equal or higher as compared to other tested agents.
authors.affiliation: Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. Electronic address: andrej.weintraub@ki.se.
authors.forename: Andrej
authors.initials: A
authors.lastname: Weintraub
authors.affiliation: Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Mamun-Ur
authors.initials: MU
authors.lastname: Rashid
authors.affiliation: Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
authors.forename: Carl Erik
authors.initials: CE
authors.lastname: Nord
mesh_terms: D019980:Amoxicillin-Potassium Clavulanate Combination / Q000494:pharmacology; D000693:Anaerobiosis; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D001421:Bacteria, Anaerobic; D002443:Ceftriaxone / Q000494:pharmacology; D000069196:Gastrointestinal Microbiome / Q000187:drug effects* / Q000502:physiology; D041981:Gastrointestinal Tract / Q000382:microbiology; D006089:Gram-Negative Anaerobic Bacteria / Q000187:drug effects* / Q000254:growth & development; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000254:growth & development; D006801:Humans; D064704:Levofloxacin / Q000494:pharmacology; D018942:Macrolides / Q000494:pharmacology*; D008795:Metronidazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D013045:Species Specificity; D014230:Triazoles / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D018942:Macrolides; D014230:Triazoles; D008795:Metronidazole; D064704:Levofloxacin; D019980:Amoxicillin-Potassium Clavulanate Combination; D002443:Ceftriaxone; D017963:Azithromycin; C547755:solithromycin
keywords: Anaerobes; Normal intestinal microbiota; Solithromycin